[Oxaliplatin and genito-urinary tumors].
Considering genito-urinary tumors, the use of oxaliplatin should be restricted to clinical trials since no marketing approval has been obtained. Results of prospective studies currently suggest that the development of oxaliplatin should be carried on with first-line management of poor prognosis metastatic germ cell tumors as well as metastatic bladder cancer patients not eligible for cisplatin therapy.
CRC Val d'Aurelle, Parc Euromédecine, 34298 Montpellier Cedex 5. stculine@valdorel.fnclcc.fr
Stéphane
S
Culine
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077150:Oxaliplatin; D014565:Urogenital Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin